| 1 |
左晓飞，范华菊，吴倩盈，等. 硼化镁纳米颗粒通过上调BDNF减轻海马神经元及突触损伤改善糖尿病并发抑郁症小鼠行为和脑结构异常[J]. 陆军军医大学学报，2026, 48(17): 2440-2452.
|
| 2 |
Xu Y, Lu J, Li M, et al. Diabetes in China part 1: Epidemiology and risk factors[J]. Lancet Public Health, 2024, 9(12): e1089-e1097.
|
| 3 |
Jia W, Chan JC, Wong TY, et al. Diabetes in China: epidemiology, pathophysiology and multi-omics[J]. Nat Metab, 2025, 7(1): 16-34.
|
| 4 |
Diagnosis and classification of diabetes: standards of care in diabetes-2025[J]. Diabetes Care, 2025, 48(Supplement_1): S27-S49.
|
| 5 |
Holt RIG, Cockram CS, Ma RCW, et al. Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment[J]. Diabetologia, 2024, 67(7): 1168-1180.
|
| 6 |
Kontsevaya I, Cabibbe AM, Cirillo DM, et al. Update on the diagnosis of tuberculosis[J]. Clin Microbiol Infect, 2024, 30(9): 1115-1122.
|
| 7 |
Litvinjenko S, Magwood O, Wu S, et al. Burden of tuberculosis among vulnerable populations worldwide: an overview of systematic reviews[J]. Lancet Infect Dis, 2023, 23(12): 1395-1407.
|
| 8 |
Franco JV, Bongaerts B, Metzendorf MI, et al. Diabetes as a risk factor for tuberculosis disease[J]. Cochrane Database Syst Rev, 2024, 8(8): CD016013.
|
| 9 |
Li M, Chen T, Hua Z, et al. Global, regional, and national prevalence of diabetes mellitus in patients with pulmonary tuberculosis: a systematic review and meta-analysis[J]. Diabetol Metab Syndr, 2021, 13(1): 127.
|
| 10 |
周勇，闫世春，韩雪，等. 2017-2021年黑龙江省肺结核合并糖尿病登记率及变化趋势[J]. 疾病监测，2023, 38(04): 426-431.
|
| 11 |
黄涛，菅辉勇，王新旗，等. 新疆维吾尔自治区肺结核合并糖尿病患者治疗转归影响因素分析[J] 中国防痨杂志，2024, 46(9): 1083-1088.
|
| 12 |
杨蕊，李玲，陈金瓯，等. 2017-2021年云南省肺结核与糖尿病共病患者抗结核治疗效果及影响因素分析[J].中国防痨杂志，2024, 46(5): 519-524.
|
| 13 |
Huangfu P, Ugarte-Gil C, Golub J, et al. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis[J]. Int J Tuberc Lung Dis, 2019, 23(7): 783-796.
|
| 14 |
郭晶，庞加磊，高卫卫，等. 2019-2021年南京地区成人活动性肺结核合并糖尿病患者表型耐药特征分析[J]中国防痨杂志，2024, 46(1): 62-69.
|
| 15 |
Tegegne BS, Mengesha MM, Teferra AA, et al. Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis[J]. Syst Rev, 2018, 7(1): 161.
|
| 16 |
Cheng P, Wang L, Gong W. Cellular Immunity of patients with tuberculosis combined with diabetes[J]. J Immunol Res, 2022, 2022: 6837745.
|
| 17 |
Scriba TJ, Maseeme M, Young C, et al. Immunopathology in human tuberculosis[J]. Sci Immunol, 2024, 9(102): eado5951.
|
| 18 |
Flynn JL, Chan J. Immune cell interactions in tuberculosis[J]. Cell, 2022, 185(25): 4682-4702.
|
| 19 |
Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis[J]. Nat Rev Microbiol, 2022, 20(12): 750-766.
|
| 20 |
Ayelign B, Negash M, Genetu M, et al. Immunological impacts of diabetes on the susceptibility of Mycobacterium tuberculosis[J]. J Immunol Res, 2019, 2019: 6196532.
|
| 21 |
Kumar NP, Babu S. Impact of diabetes mellitus on immunity to latent tuberculosis infection[J]. Front Clin Diabetes Healthc, 2023, 4: 1095467.
|
| 22 |
Hair PS, Echague CG, Rohn RD, et al. Hyperglycemic conditions inhibit C3-mediated immunologic control of Staphylococcus aureus[J]. J Transl Med, 2012, 10: 35.
|
| 23 |
Dowey R, Iqbal A, Heller SR, et al. A bittersweet response to infection in diabetes; targeting neutrophils to modify inflammation and improve host immunity[J]. Front Immunol, 2021, 12: 678771.
|
| 24 |
Usero L, Sánchez A, Pizarro E, et al. Interleukin-13 pathway alterations impair invariant natural killer t-cell-mediated regulation of effector t cells in type 1 diabetes[J]. Diabetes, 2016, 65(8): 2356-2366.
|
| 25 |
Ssekamatte P, Sande OJ, Van Crevel R, et al. Immunologic, metabolic and genetic impact of diabetes on tuberculosis susceptibility[J]. Front Immunol, 2023, 14: 1122255.
|
| 26 |
Clayton SM, Shafikhani SH, Soulika AM. Macrophage and neutrophil dysfunction in diabetic wounds[J]. Adv Wound Care (New Rochelle), 2024, 13(9): 463-484.
|
| 27 |
Nobs SP, Kolodziejczyk AA, Adler L, et al. Lung dendritic-cell metabolism underlies susceptibility to viral infection in diabetes[J]. Nature, 2023, 624(7992): 645-652.
|
| 28 |
Kumar NP, Sridhar R, Banurekha VV, et al. Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus[J]. J Infect Dis, 2013, 208(5): 739-748.
|
| 29 |
Rajamanickam A, Kothandaraman SP, Kumar NP, et al. Cytokine and chemokine profiles in pulmonary tuberculosis with pre-diabetes[J]. Front Immunol, 2024, 15: 1447161.
|
| 30 |
Buasroung P, Petnak T, Liwtanakitpipat P, et al. Prevalence of diabetes mellitus in patients with tuberculosis: a prospective cohort study[J]. Int J Infect Dis, 2022, 116: 374-379.
|
| 31 |
Daryabor G, Atashzar M R, Kabelitz D, et al. The effects of type 2 diabetes mellitus on organ metabolism and the immune system[J]. Front Immunol, 2020, 11: 1582.
|
| 32 |
Martinez N, Smulan LJ, Jameson ML, et al. Glycerol contributes to tuberculosis susceptibility in male mice with type 2 diabetes[J]. Nat Commun, 2023, 14(1): 5840.
|
| 33 |
Cordeiro Da Costa J, Oliveira O, Baía L, et al. Prevalence and factors associated with diabetes mellitus among tuberculosis patients: a nationwide cohort[J]. Eur Respir J, 2016, 48(1): 264-268.
|
| 34 |
Segura-Cerda CA, López-Romero W, Flores-Valdez MA. Changes in host response to Mycobacterium tuberculosis infection associated with type 2 diabetes: beyond hyperglycemia[J]. Front Cell Infect Microbiol, 2019, 9: 342.
|
| 35 |
Kumar NP, Moideen K, Nancy A, et al. Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy[J]. BMC Infect Dis, 2019, 19(1): 1039.
|
| 36 |
Lagman M, Ly J, Saing T, et al. Investigating the causes for decreased levels of glutathione in individuals with type Ⅱ diabetes[J]. PLoS One, 2015, 10(3): e0118436.
|
| 37 |
Vankayalapati A, Durojaye O, Mukherjee T, et al. Metabolic changes enhance necroptosis of type 2 diabetes mellitus mice infected with Mycobacterium tuberculosis[J]. PLoS Pathog, 2024, 20(5): e1012148.
|
| 38 |
Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes[J]. Nat Rev Immunol, 2019, 19(12): 734-746.
|
| 39 |
Chen HG, Liu M, Jiang SW, et al. Impact of diabetes on diagnostic delay for pulmonary tuberculosis in Beijing[J]. Int J Tuberc Lung Dis, 2014, 18(3): 267-271.
|
| 40 |
Martinez N, Kornfeld H. Tuberculosis and diabetes: from bench to bedside and back[J]. Int J Tuberc Lung Dis, 2019, 23(6): 669-677.
|
| 41 |
Yew WW, Chang KC, Chan DP. Oxidative Stress and first-line antituberculosis drug-induced hepatotoxicity[J]. Antimicrob Agents Chemother, 2018, 62(8).DOI： 10.1128/AAC.02637-17
|
| 42 |
Medellín-Garibay SE, Cortez-Espinosa N, Milán-Segovia RC, et al. Clinical pharmacokinetics of rifampin in patients with tuberculosis and Type 2 diabetes mellitus: Association with biochemical and Immunological parameters[J]. Antimicrob Agents Chemother, 2015, 59(12): 7707-7714.
|
| 43 |
Kornfeld H, Sahukar SB, Procter-Gray E, et al. Impact of diabetes and low body mass index on tuberculosis treatment outcomes[J]. Clin Infect Dis, 2020, 71(9): e392-e398.
|
| 44 |
Ren Y, Ren H, Tian Q, et al. The relationship between computed tomography appearance of pulmonary tuberculosis and blood glucose levels in 763 diabetes mellitus patients with pulmonary tuberculosis: a comparative study[J]. Endocrine, 2022, 76(3): 584-592.
|
| 45 |
Panic N, Maetzel H, Bulajic M, et al. Pancreatic tuberculosis: A systematic review of symptoms, diagnosis and treatment[J]. United European Gastroenterol J, 2020, 8(4): 396-402.
|
| 46 |
Kelestimur F. The endocrinology of adrenal tuberculosis: the effects of tuberculosis on the hypothalamo-pituitary-adrenal axis and adrenocortical function[J]. J Endocrinol Invest, 2004, 27(4): 380-386.
|
| 47 |
Magee MJ, Salindri AD, Kyaw NTT, et al. Stress hyperglycemia in patients with tuberculosis disease: epidemiology and clinical implications[J]. Curr Diab Rep, 2018, 18(9): 71.
|
| 48 |
Trajman A, Campbell JR, Kunor T, et al. Tuberculosis[J]. Lancet, 2025, 405(10481): 850-866.
|
| 49 |
Pérez-Martínez DE, Bermúdez-Hernández GA, Madrazo-Moya CF, et al. SNPs in genes related to DNA damage repair in Mycobacterium tuberculosis: their association with type 2 diabetes mellitus and drug resistance[J]. Genes (Basel), 2022, 13(4).DOI： 10.3390/genes13040609.
|
| 50 |
Pradipta IS, Forsman LD, Bruchfeld J, et al. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis[J]. J Infect, 2018, 77(6): 469-478.
|
| 51 |
Metwally AS, El-Sheikh SMA, Galal AA. The impact of diabetes mellitus on the pharmacokinetics of rifampicin among tuberculosis patients: A systematic review and meta-analysis study[J]. Diabetes Metab Syndr, 2022, 16(2): 102410.
|
| 52 |
Wattanapokayakit S, Mushiroda T, Yanai H, et al. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients[J]. Int J Tuberc Lung Dis, 2016, 20(10): 1364-1369.
|
| 53 |
Kumar AKH, Kadam A, Karunaianantham R, et al. Effect of metformin on plasma exposure of rifampicin, isoniazid, and pyrazinamide in patients on treatment for pulmonary tuberculosis[J]. Ther Drug Monit, 2023, 46(3): 370-375.
|
| 54 |
Huang LK, Wang HH, Lai YC, et al. The impact of glycemic status on radiological manifestations of pulmonary tuberculosis in diabetic patients[J]. PLoS One, 2017, 12(6): e0179750.
|
| 55 |
Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management[J]. J Clin Exp Hepatol, 2012, 3(1): 37-49.
|
| 56 |
Te Brake LHM, Yunivita V, Livia R, et al. Rifampicin alters metformin plasma exposure but not blood glucose levels in diabetic tuberculosis patients[J]. Clin Pharmacol Ther, 2018, 105(3): 730-737.
|
| 57 |
Sutter A, Landis D, Nugent K. The potential role for metformin in the prevention and treatment of tuberculosis[J]. J Thorac Dis, 2022, 14(6): 1758-1765.
|
| 58 |
Zhou J, Massey S, Story D, et al. Metformin: an old drug with new applications[J]. Int J Mol Sci, 2018, 19(10).DOI： 10.3390/ijms19102863
|
| 59 |
Lee YJ, Han SK, Park JH, et al. The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus[J]. Korean J Intern Med, 2018, 33(5): 933-940.
|
| 60 |
Lee MC, Lee CH, Lee MR, et al. Impact of metformin use among tuberculosis close contacts with diabetes mellitus in a nationwide cohort study[J]. BMC Infect Dis, 2019, 19(1): 936.
|
| 61 |
Kumar AKH, Kadam A, Karunaianantham R, et al. Effect of metformin on plasma exposure of rifampicin, isoniazid, and pyrazinamide in patients on treatment for pulmonary tuberculosis[J]. Ther Drug Monit, 2024, 46(3): 370-375.
|
| 62 |
Radhakrishnan RK, Thandi RS, Tripathi D, et al. BCG vaccination reduces the mortality of Mycobacterium tuberculosis-infected type 2 diabetes mellitus mice[J]. JCI Insight, 2020, 5(5).DOI： 10.1172/jci.insight.133788.
|
| 63 |
Zhen J, Zhang C, Huang T, et al. Drug repurposing: an antidiabetic drug Ipragliflozin as Mycobacterium tuberculosis sirtuin-like protein inhibitor that synergizes with anti-tuberculosis drug isoniazid[J]. Int J Biol Macromol, 2024, 282(Pt 3): 137003.
|